Bioregulator ResearchRead More →
Vilon Research
An evidence-led look at Vilon research: how independent the literature is, animal findings including an adverse one, and a computational DNA mechanism.
Dr. Tharindunee Jayakody
August 27, 2026
Bioregulator Research
Testagen Research
Dr. Tharindunee JayakodyPhDPublished 27 August 2026
Testagen is a short synthetic peptide sold as a "peptide bioregulator." This page sets out what has been published about it, which is very little.
Research-grade Testagen is supplied as a laboratory research chemical. It is not for human consumption.
What Testagen is
Testagen is a tetrapeptide, four amino acids long. Its sequence is Lys-Glu-Asp-Gly, written KEDG or H-Lys-Glu-Asp-Gly-OH [1][2].
Its identity is thin in the chemical databases. The US National Library of Medicine holds a record for lysyl-glutamyl-aspartyl-glycine, but that record does not carry "Testagen" as an entry term [3]. A structure search of PubChem returns CID 123863700, formula C17H29N5O9, molecular weight 447.4. That record is unnamed and carries no CAS number [3].
Testagen also sits inside a nested series. It shares its first three residues with a shorter peptide in the same catalogue, and differs from several siblings only in its final residue [4]. No published study compares any of them head to head. On what functionally separates Testagen from the peptides it contains or resembles, the literature is silent.
The entire published literature
A PubMed search on the name returned exactly two records on 27 August 2026 [5]. That is all of it.
The first is a 2011 in vitro study from the originating institute's network [2]. It incubated HeLa cells with fluorescein-tagged versions of three peptides, one of them Testagen, and reported fluorescence in the cytoplasm, nucleus and nucleolus. It also reported that quenching constants for labeled oligonucleotides "were different depending on the peptide primary structures" [2]. Two limits matter here. The peptides carried a fluorescent tag that roughly doubles the mass of a tetrapeptide and is itself membrane-permeant and nucleolus-accumulating. The result is shared across the tested set rather than specific to Testagen.
The second record is not biology at all. It is a 2025 materials chemistry paper from the University of Craiova in Romania, testing KEDG as a corrosion inhibitor on copper in saline [1]. It is cited here only because it states the sequence unambiguously. It contains no biological assay and has no bearing on any health claim.
Searching by sequence code rather than trade name surfaces two further multi-peptide screens in which KEDG appears alongside five or more relatives. One is an in vitro study of binding to wheat histones [6]. The other is computational docking [4]. Neither reports a result belonging to Testagen alone.
What has not been studied
There is no clinical study of Testagen in people, and no human data of any kind [7].
There is no pharmacokinetic study of Testagen in humans or animals [8]. No study has measured whether it survives digestion or reaches the bloodstream intact. PepT1, the intestinal transporter that carries small peptides across the gut wall, transports di- and tripeptides only [9]. Testagen is a tetrapeptide, so it has no known carrier-mediated route of intact oral absorption. That is an inference from transporter biology, not an experiment on this compound.
There is no lifespan, longevity or survival study of Testagen in any species [8]. No formal toxicology package has been published, and absence of published toxicology is not evidence of safety.
A ClinicalTrials.gov search on 27 August 2026 returned one hit for the term Testagen [10]. It is NCT02733133, a product transference study of "Testagen TDS-Testosterone," a transdermal testosterone product. That is a trade name collision and does not involve the KEDG peptide. No registered clinical trial of this compound exists.
Family background
The following describes the wider group of peptides, not Testagen, and is offered as context only.
The institute that developed these compounds also patented them and sells them. Its founder is a named co-inventor on granted patents in the family. Papers from that network nonetheless declare no conflict of interest, including a 2020 statement that each author has no "patent/licensing arrangement" [11]. None of this is evidence about Testagen, which has almost no literature to weigh either way.
Frequently Asked Questions
Is there any human data on Testagen?
No. There is no clinical study of Testagen in people, and no human data of any kind [7]. Its entire named literature is one in vitro study in HeLa cells, shared with two other peptides [2], plus one materials chemistry paper on copper corrosion [1]. A ClinicalTrials.gov search on 27 August 2026 returned only an unrelated transdermal testosterone product [10].
Why do searches for Testagen return a testosterone trial and a corrosion study?
Both are traps for the unwary. NCT02733133 is "Testagen TDS-Testosterone," a transdermal testosterone product unrelated to the KEDG peptide [10]. The 2025 Molecules paper does test the KEDG peptide, but as a copper corrosion inhibitor in saline, with no biological assay [1]. Neither says anything about what Testagen does in a living organism.
References
- 3NLM MeSH supplementary concept record C560777 and PubChem CID 123863700, database lookups run 27 August 2026. No identifier.
- 5PubMed E-utilities record count for the term "testagen," run 27 August 2026. No identifier.
- 7PubMed searches for Testagen combined with human, patients and clinical, run 27 August 2026. No identifier.
- 8PubMed searches for Testagen and KEDG against pharmacokinetic, lifespan, longevity, survival and mortality endpoints, run 27 August 2026. No identifier.
- 10ClinicalTrials.gov API v2 search, run 27 August 2026. Record NCT02733133. No identifier.
Reviewed & approved for scientific accuracy
Dr. Tharindunee Jayakody
PhD — Scientific Contributor and Reviewer
Dr Jayakody is a molecular pharmacologist with over 15 years of experience in translating complex research into clear, evidence-based explanations, with expertise on peptide therapeutics and other emerging compounds, particularly in delineating the mechanisms of action of therapeutics. As a contributor to research-focused platforms, Dr Jayakody aims to give scientifically literate readers a balanced view of what current data can and cannot support, helping them understand how promising findings in the lab translate, or sometimes fail to translate, into real-world applications.
View team profile →Related Articles
Bioregulator ResearchRead More →
Vesugen Research
An evidence-led look at Vesugen research: identity and naming, its presence inside four other products, and two uncontrolled human reports.
Dr. Tharindunee Jayakody
August 27, 2026
Bioregulator ResearchRead More →
Thymalin Research
An evidence-led look at Thymalin research: what the preparation actually is, the COVID-19 trial, the older human literature, and what is unproven.
Dr. Tharindunee Jayakody
August 27, 2026